Analysts Expect Champions Oncology Inc (CSBR) to Announce $0.03 Earnings Per Share

Champions Oncology Inc (NASDAQ:CSBR) has earned an average broker rating score of 1.00 (Strong Buy) from the three brokers that provide coverage for the stock, Zacks Investment Research reports. Three research analysts have rated the stock with a strong buy rating.

Analysts have set a 12 month consensus price objective of $14.33 for the company and are anticipating that the company will post $0.03 earnings per share for the current quarter, according to Zacks. Zacks has also given Champions Oncology an industry rank of 86 out of 256 based on the ratings given to its competitors.

Separately, Zacks Investment Research raised shares of Champions Oncology from a “hold” rating to a “strong-buy” rating and set a $12.00 target price for the company in a research note on Monday, September 17th.

In other Champions Oncology news, CEO Ronnie Morris purchased 20,000 shares of the business’s stock in a transaction on Wednesday, December 19th. The stock was acquired at an average price of $7.44 per share, with a total value of $148,800.00. Following the acquisition, the chief executive officer now directly owns 833,001 shares of the company’s stock, valued at approximately $6,197,527.44. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Daniel Newman Mendelson sold 5,000 shares of the firm’s stock in a transaction on Tuesday, November 6th. The shares were sold at an average price of $13.75, for a total value of $68,750.00. Following the sale, the director now directly owns 57,500 shares of the company’s stock, valued at approximately $790,625. The disclosure for this sale can be found here. 44.30% of the stock is currently owned by company insiders.

A number of institutional investors have recently made changes to their positions in the business. Renaissance Technologies LLC lifted its holdings in Champions Oncology by 164.3% during the 3rd quarter. Renaissance Technologies LLC now owns 265,846 shares of the biotechnology company’s stock valued at $4,644,000 after purchasing an additional 165,246 shares during the last quarter. Vanguard Group Inc. lifted its holdings in Champions Oncology by 51.4% during the 3rd quarter. Vanguard Group Inc. now owns 231,150 shares of the biotechnology company’s stock valued at $4,038,000 after purchasing an additional 78,428 shares during the last quarter. Vanguard Group Inc lifted its holdings in Champions Oncology by 51.4% during the 3rd quarter. Vanguard Group Inc now owns 231,150 shares of the biotechnology company’s stock valued at $4,038,000 after purchasing an additional 78,428 shares during the last quarter. Perkins Capital Management Inc. lifted its holdings in Champions Oncology by 75.3% during the 3rd quarter. Perkins Capital Management Inc. now owns 180,600 shares of the biotechnology company’s stock valued at $3,155,000 after purchasing an additional 77,600 shares during the last quarter. Finally, EAM Investors LLC acquired a new stake in Champions Oncology during the 3rd quarter valued at $3,144,000. 49.99% of the stock is owned by institutional investors and hedge funds.

Shares of CSBR opened at $9.25 on Tuesday. The company has a market cap of $95.93 million, a PE ratio of -66.07 and a beta of 1.21. Champions Oncology has a twelve month low of $3.05 and a twelve month high of $17.90. The company has a debt-to-equity ratio of 0.05, a current ratio of 0.94 and a quick ratio of 0.94.

Champions Oncology (NASDAQ:CSBR) last issued its quarterly earnings results on Monday, December 17th. The biotechnology company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.01). The business had revenue of $6.69 million for the quarter, compared to the consensus estimate of $6.35 million. Champions Oncology had a return on equity of 1.44% and a net margin of 0.05%. As a group, sell-side analysts expect that Champions Oncology will post 0.15 EPS for the current fiscal year.

Champions Oncology Company Profile

Champions Oncology, Inc engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice.

Read More: What is Net Asset Value (NAV)?

Get a free copy of the Zacks research report on Champions Oncology (CSBR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Champions Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Champions Oncology and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit